Brain cancer in 2012: Molecular characterization leads the way

Nature Reviews Clinical Oncology

Volumn 10, Issue 2, 2013, Pages 69-70

  Stupp, Roger ^a   Hegi, Monika E ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; LOMUSTINE; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; DNA REPAIR; EPIGENETICS; GENE DELETION; GENE SILENCING; GLIOBLASTOMA; HUMAN; METHYLATION; METHYLGUANINE METHYLTRANSFERASE GENE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROMOTER REGION; REVIEW; SEQUENCE ANALYSIS; TUMOR GENE;

BRAIN NEOPLASMS; GENE EXPRESSION PROFILING; HUMANS; MOLECULAR TARGETED THERAPY; TIME FACTORS;

EID: 84873411117     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2012.240     Document Type: Review

References (9)

1. Wick, W. et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA08 randomised, phase 3 trial. Lancet Oncol. 13, 707-715 (2012).
2. Malmström, A. et al. Temozolomide versus standard 6week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol. 13, 916-926 (2012).
3. van den Bent, M. J. et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC Brain Tumor Group Study 26951. J. Clin. Oncol. http://dx.doi.org/10.1200/JCO.2012.43.2229.
4. Shaw, E. G. et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. J. Clin. Oncol. 30, 3065-3070 (2012).
5. Chinot, O. et al. Roche study showed that Avastin helped people with newly diagnosed gliobastoma live longer without their disease worsening when added to radiation and chemotherapy. F. Hoffmann-La Roche Ltd [online], http://www.roche.com/media/media-releases/med-cor-2012-11-17.htm (2012).
6. Stupp, R. et al. NovoTTF100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur. J. Cancer 48, 2192-2202 (2012).
7. Choi, C. et al. 2hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat. Med. 18, 624-629 (2012).
8. Northcott, P. A., Korshunov, A., Pfister, S. M. & Taylor, M. D. The clinical implications of medulloblastoma subgroups. Nat. Rev. Neurol. 8, 340-351 (2012).
9. Robinson, G. et al. Novel mutations target distinct subgroups of medulloblastoma. Nature 488, 43-48 (2012).